Summary Monoclonal antibodies were raised against human placental soluble E-cadherins and used in an immunoenzymometric assay to detect soluble E-cadherins in biological fluids. The E-cadherin assay was accurate enough to quantitate the concentration of soluble E-cadherin in the cell culture supernatants. Immunoreactive E-cadherins, identified as existing in the soluble form in normal serum, were shown to have apparent lower molecular mass (approximately 80 kDa) than intact molecules of E-cadherin. We found that the immunoreactive E-cadherin levels in the serum of the studied cancer patients were significantly elevated (mean ± s.d. 3.80 ± 2.36 tig ml', P<0.0001) when compared with the normal levels (1.99 ± 0.50 1tg ml-'). We also found that serum E-cadherin levels in the 22 patients with gastric cancer (3.51 ± 1.78 tLg ml-, P <0.02) or the 11 patients with hepatocellular cancer (5.55 ± 3.11 Lg ml-', P<0.001) were significantly higher than those in the 26 diabetic patients (2.33 ± 1.58 iLg ml-'). Of the 54 cancer patients, 53.7% exhibited an elevated amount of soluble E-cadherin in serum. Thus, it is evident that soluble E-cadherin in circulation can be used as a prospective tumour marker that accurately reflects the progressive regeneration of E-cadherin at tumour sites, potentially induced by tumour-associated proteolytic degradation.
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Cadherins are Ca2"-dependent cell adhesion molecules which play an essential role in normal growth and development via mediation of homotypic, homophilic cell-cell association (Takeichi, 1988) . A variety of subclasses of cadherins have already been identified (Suzuki et al., 1991) . Three of them, namely E-, N-and P-cadherin, share a common primary structure and mediate cell-cell adhesion in a homophilic and subclass-specific manner (Takeichi, 1991) . E-cadherin, also termed uvomorulin or Cell-CAM120/80, is a cell-adhesive molecule found in epithelial cells in a variety of embryonic and adult tissues (Damsky et al., 1983; Ogou et al., 1983; Vestweber & Kemler, 1984) . Several recent studies suggested that loss of E-cadherin may be associated with tumour progression in epidermal carcinogenesis as well (Navarro et al., 1991) , and E-cadherin acts particularly as a suppressor of invasive ability (Behrens et al., 1989; Chen & Obrink, 1991; Frixen et al., 1991; Mareel et al., 1991; Vleminckx et al., 1991) or metastatic phenotype (Hashimoto et al., 1989; Schipper et al., 1991) . In adult organisms, each cadherin displays a characteristic tissue distribution pattern, although expression is not tissue specific (Takeichi, 1991) . Many immunohistochemical studies searching for tissue distribution of cadherins have demonstrated that unstable or reduced expression of E-cadherin seems to be a common event in cancer progression, e.g. in lung carcinoma (Shimoyama et al., 1989) , gastric tumours (Shimoyama & Hirohashi, 1991a) , hepatocellular carcinoma (Shimoyama & Hirohashi, 1991b) , breast carcinoma (Rasbridge et al., 1993) and prostatic tumours (Bussemakers et al., 1992; Umbas et al., 1992) .
Soluble forms of E-cadherin were firstly investigated as 80-84 kDa peptides released from MCF-7 human carcinoma cells into the serum-free culture medium or artificially generated by trypsinising cells in the presence of calcium (Damsky et al., 1983) . They retain the functional activities themselves to disrupt cell-cell contact in cultured epithelial cells, and antibodies raised against them also induce disruption of mutual adhesion of the target cells (Wheelock et al., 1987) . Therefore, the 80 kDa peptide is probably a degradation product of the 120 kDa form of intact E-cadherin generated by a Ca2+ ion-dependent proteolytic action (Wheelock et al., 1987; Takeichi, 1988 ability to react with antigen immobilised on the microtitre plates, or to preferentially bind with the fixed human vulvar epidermoid carcinoma cell line A431 (Giard et al., 1973) on the culture dish, which was prepared by fixing cultured cells spreading on the plates directly with the solution of 99% ethanol and 1% acetic acid at 4°C for 3 min.
Immunoblotting
The immunoreactivities of the established MAbs to Ecadherin expressed on A431 cells were analysed by immunoblotting as described previously (Yoshida-Noro et al., 1984) with slight modification. In brief, monolayers of A431 cells (1 x 106 cells) were incubated with 5 ml of solution of physiological saline containing 1 mmol 1-EDTA and 0.01% trypsin, 0.01% trypsin plus 5 mmol 1' calcium chloride or only 5 mmol 1i calcium chloride at 37°C for 20 min. Treated cells were isolated by gentle pipetting or by using cell scrapers (Becton Dickinson, Lincoln Park, NJ, USA), centrifuged at 800 g for O min, and the supernatant was separated from the insoluble cellular materials. The cells and supernatants were then extracted with 4% sodium dodecyl sulphate (SDS) electrophoresis sample solution (0.1 mol 1-' Tris-HCI, 5% P-mercaptoethanol, 20% glycerol, 0.005% bromophenol blue, pH 7.6) at a volume ratio of 1:1, subjected to 5-20% SDS-polyacrylamide gel electrophoresis (PAGE), and transferred onto the polyvinylidine difluoride (PVDF) membrane (Millipore, Bedford, MA, USA). The membranes were blocked by TBS containing 0.1% skimmed milk and incubated in the hybridoma culture supernatants for 4 h at room temperature. Immunoreactive proteins on the membranes were visualised by peroxidase-labelled anti-mouse IgG (Amersham International, Amersham, UK) and 4-chloro-l-naphthol substrate (Nacalai Tesque, Kyoto, Japan).
A 100 pl aliquot of serum from the clinical subjects was incubated with 30 jg of SHE13-6 MAb immobilised on CNBr-activated Sepharose 4B gel for 0.5 h at 4°C, and washed twice with TBS containing 0.1% sodium azide. These gels were directly mixed with the above sample solution, boiled at 100°C for 2 min, and their resulting supernatants separated by centrifugation at 4°C were subjected to the immunoblotting analysis exactly according to the above procedures.
IEMA procedure Among the obtained MAbs directed to soluble E-cadherin isolated from human placenta, SHE13-6 was found to show the highest reactivity with soluble E-cadherin. The IEMA using MAbs was performed as previously described (Katayama et al., 1992) with slight modifications. SHE13-6 and HECD-1 MAbs were isolated by ammonium precipitation from mouse ascites, and further purified by Mono-Q ion-exchange chromatography in the fast protein liquid chromatography system (Pharmacia LKB). Purified soluble E-cadherin was used as the IEMA standard. Purified SHE13-6 was conjugated with horseradish peroxidase (Boehringer Mannheim, Germany) using the periodate method as described previously (Harlow & Lane, 1988 
Subjects
We studied serum samples collected from a total of 140 individuals, including 56 healthy subjects, 26 patients with diabetes mellitus, four patients with acute hepatitis and 54 cancer patients. There were 21 male, 29 female and six volunteers whose genders are not specified among these healthy subjects, whose serum samples were generously provided by M. Handa (Blood Center, Keio University Hospital, Tokyo, Japan). The primary tumour site of the cancer patients in this study was either the stomach (n = 22), the liver (n = 11), the pancreas (n = 1), the colon, the rectum (n = 4) or the ovary (n = 1). Patients with leiomyosarcoma (n = 4) and patients with leukaemia, including five patients with myelogenous leukaemia, three with monocytic leukaemia and three with lymphatic leukaemia (n = 11), were also included among the cancerous subjects. Serum samples of the 54 cancer patients, the 26 non-malignant patients with diabetes mellitus, and the four non-malignant patients with acute hepatitis were received from Takeda Hospital (Kyoto, Japan). All of the 54 cancer patients with pathologically and histologically proven cancer, but with no previous treatment by chemotherapy and radiotherapy, were included in this study. All the specimens of the 54 cancer patients were collected before surgery. Ca2", and not to bind to A431 lysates prepared in the absence of Ca2" (Figure 1 ), demonstrating that HECD-1
MAb was specific for human E-cadherin. In another Western blotting analysis, we also found that SHE13-6 could recognise soluble 80kDa fragments of E-cadherin isolated from human placenta as well as HECD-1. selected from the subjects used in this study. About 75-80 kDa E-cadherin molecules present in serum were detected by peroxidase-labelled HECD-l MAbs and substrates (Figure 4 ). The molecular weights of soluble E-cadherins of several serum samples, from either healthy subjects or cancer patients, were almost all identical ( Figure  4 , lanes B-J). HECD-1 MAb could also bind to E-cadherins at the approximate molecular weight of 10 kDa in the whole-cell lysate of A431, which consisted of intact membrane-associated molecules (Figure 4, lane A) .
Soluble E-cadherin releasedfrom cultured cells Physiological concentrations of Ca2" and Mg2" both approximate to 0.4 mmol l'. The release of soluble E-cadherins increased with the elevation of EDTA concentrations, ranging from 0.0625 to 0.5 mmol I`, in the culture medium.
Immunoreactive soluble E-cadherins completely disappeared in the culture fluids at EDTA concentrations of 1 mmol 1-' or higher, because at these concentrations EDTA was recognised to chelate all of the divalent cations in the culture medium, and E-cadherin on the cell surface was greatly degraded into undetectable smaller fragments (Yoshida & Takeichi, 1982) . Discussion E-cadherin was supposed to exist in serum in the monomeric soluble form, because the same concentrations were recovered accurately along the linear dilution curves on the IEMA quantitation (Figure 2 Figure 5 ). We identified from this study, as well as from results obtained previously (Yoshida & Takeichi, 1982) , that coexistent Ca2+ is necessary to stabilise the structure of soluble E-cadherin immunoreactive with those MAbs. Several reports have stated that metastatic tumour cells might be less homotypically adhesive than their non-metastatic counterparts, especially in immunological analysis for the homotypic cell-cell adhesion molecules, but their conclusions appear to be conflicting (Lotan & Raz, 1983; Hixson et al., 1985; Reeves, 1992) . In contrast to the other cell-cell adhesive receptors, dysfunction in the regulation of cadherin expression might very well be involved in cancer development and progression (Takeichi, 1991; Umbas et al., 1992) . Furthermore, E-cadherin is well known to be an invasive suppressor in tumour progressions, because expression levels for E-cadherins were reduced in almost all the malignant tumours and not correlated with their metastatic abilities (Behrens et al., 1989; Hashimoto et al., 1989) . Additionally, a recent report suggested the possibility that some carcinoma cells lose E-cadherin expression during the process of detaching from the primary sites and infiltrating other sites (Matsuura et al., 1992) ; another elucidated that some Ecadherin functions expressed on the cancerous cell surfaces are impaired by loss or down-regulation of cytoplasmic proteins designated 'catenins' (Shimoyama et al., 1992) . Here, we understand that E-cadherin dysfunction in tumour cells was partly mediated by the degradation of proteases secreted from these cells, because soluble E-cadherin with a molecular weight of about 80 kDa remarkably increased in the circulation of cancer patients (Figure 4) , and it can reasonably be derived from proteolytic digests of the cell-surface Ecadherin.
Healthy individuals appear to have continuous E-cadherin regeneration and to process a small amount of soluble Ecadherin into the blood flow, resulting in a serum E-cadherin concentration of 2 #g ml-' (Figure 3) . However, elevated levels of soluble E-cadherin were detected more frequently in malignant patients but not in the patients with diabetes mellitus or acute hepatitis (Figure 3) . Thus, we suggest that proteolytic degradation of E-cadherins in cancers may be associated with malignancy, invasiveness or the metastatic ability of tumour cells at the primary sites. No significant elevation of circulating E-cadherin levels was observed in the studied non-epithelial malignancies, such as leukaemias or leiomyosarcomas, compared with the levels in the benign disease patients. This result can potentially suggest that serum E-cadherin fragments may be a clinical marker specific to detecting epithelial carcinomas. However, the relationship between soluble E-cadherin levels in the circulation and the metastatic potency of tumours needs to be evaluated in further clinical studies, e.g. using experimental organ metastasis in animal models.
Recent immunohistochemical findings of decreased Ecadherin in progressive tumours suggest that some change in the expression level of cell-surface E-cadherin apparently occurs in malignant tissues (Shimoyama & Hirohashi, 1991b; Rasbridge et al., 1993) . This is the first investigation in which soluble cadherin has been found to be present in human biological fluids. In the present study, we propounded the novel process, which is most frequent in epithelial cancers, of shedding E-cadherin from cell surfaces and releasing its fragments into the circulation. Recent reports have demonstrated that soluble forms of some cell-surface receptors that are increased in the biological fluids of cancer patients might be processed by proteolytic cleavage and retain the functional activities of their original cell-surface molecules (Symons et al., 1988; Rothlein et al., 1991) . In our preliminary observation, serum E-cadherin also interfered with cell-cell adhesion in the cultured A43 1 cells at a final concentration of 50 tg ml 1, and the disruptive effect of purified soluble Ecadherin is reversible because the cells resumed their normal morphology after removal of supplemented soluble Ecadherin (M. Katayama et al., manuscript in preparation).
Therefore, soluble E-cadherin fragments released from the cell surface constitute a mode of down-regulation of the cell-to-cell adhesiveness mediated by E-cadherin, resulting in decreased responsiveness to the adjacent cell-surface Ecadherin. The biological potency of soluble E-cadherin released from cultured cells has already been characterised in in vitro experiments (Wheelock et al., 1987) . Some PI-integrins have been shown to function as intercellular adhesion molecules in in vitro cultured keratinocytes (Larjava et al., 1990) , and therefore the function or in vivo localisation of integrin P in tumour cells is often compared with that of cadherins using immunological analysis (Pignatelli et al., 1992) . Many reports have suggested, contrary to the findings for E-cadherin, that the surface expression of integrin PI is uniformly elevated in metastatic tumour cells and potentially mediates the tight adhesion of these cells to the subendothelial matrix substratum (Feldman et al., 1991; Martin-Padura et al., 1991) . It has already been reported that soluble integrin PI is present in the human circulation and that serum levels of soluble integrin P are unlikely to be elevated in cancer patients (Katayama et al., 1991) . We observed non-correlation between soluble integrin PI and soluble E-cadherin fragments in the serum of the studied cancer patients (data not shown). On the other hand, soluble laminin in biological fluids was demonstrated to be mostly fragmented and sometimes used as a tumour marker (Brocks et al., 1986; Katayama et al., 1992) . Serum laminin levels were significantly correlated with serum E-cadherin in the cancer patients (data not shown). This fact could suggest that degradation, release and shedding of E-cadherin on the tumour cells were somehow related to the proteolytic action by those cells, required for penetrating the extracellular matrix containing laminin or collagen (Goldfarb & Liotta, 1986) .
Recently, catenin has been recognised as a most important regulator of cadherin function (Nagafuchi et al., 1991) . Although the cadherin-catenin association is lost in some tumour cell lines or disturbed by oncogenic transformation (Shimoyama et al., 1992; Hamaguchi et al., 1993) , there are no data available with regard to the prevailing mechanisms responsible for decreased E-cadherin staining in human tumour tissues (Shimoyama & Hirohashi, 1991b; Rasbridge et al., 1993) . One of the answers to this could be supplied by the previous observation that a metastatic phenotype is induced by the genetic deletion of E-cadherin as an invasion suppressor (Chen & Obrink, 1991; Vleminckx et al., 1991) . It is possible that E-cadherin degradation and shedding from the tumour cell surface is due to the increase in fragmented E-cadherin in the soluble form in the circulation of cancer patients, independent of the genetic abnormalities of cadherin or cadherin-associated molecules.
In conclusion, it is evident that soluble E-cadherin fragment in serum, detected by the two-site IEMA investigated by us for the first time, can be used as an innovative tumour marker. The levels for serum E-cadherin fragments may be used to accurately reflect the progressive regeneration of E-cadherin around epithelial tumours, and probably to monitor the recurrence of cancer patients after surgical removal of primary tumours, or to evaluate the effects of anti-cancer treatments.
